Meprobamate was first synthesized by Ludwig and Piech in 1951. Its pharmacological properties have been studied by Berger, who described it as an interneuronal blocking agent related to mephenesin (Berger, 1954; Berger, Hendley, Ludwig, and Lynes, 1956) . He noted that when it was administered to monkeys they became more manageable and did not demonstrate fear when handled. Early reports of its clinical use were favourable, patients experiencing relief from anxiety, tension, and tension headache (Borrus, 1955; Selling, 1955 (1956) found a significant degree of improvement in patients receiving meprobamate compared with placebo, whereas Raymond, Lucas, Beesley, O 'Connell, and Fraser Roberts (1957) found no significant difference from treatment with placebo. Folkson (1957) found only a small number of patients improved while receiving meprobamate and there was an appreciable incidence of toxic effects. Reports of such toxic effects have become more frequent as the use of this compound has increased (Friedman and Marmelzat, 1956 ; Council on Drugs of American Medical Association, 1957) . The aim of the present study was to determine if meprobamate has a beneficial effect on anxious patients and, if possible, to observe which symptoms improve.
Method
The design of this trial was similar to that used by Davies and Shepherd (1955) Tables I and II. Inspection of Table I shows that the random allocation of the patients into the two groups fulfilled its purpose in distributing them evenly, according to these criteria. The incidence and the severity of the symptoms (Table II) were not significantly different in the two groups. The method of comparison is described below where the results are considered; it has not only been applied to the whole group of patients shown in Table II , but also to the group of patients who completed the trial.
The assessment of psychotherapeutic or environmental change during the trial showed no significant patients improved subjectively and objectively. The two groups were compared statistically by comparing the proportions improved in each. For these comparisons arc sine transformation of the square roots of the proportions (to achieve normality of distribution) were employed and the critical ratios (C.R.) calculated (Davies, 1954) . The probability levels (P) of these critical ratios were then noted. In some instances x2 tests, using Yates' correction, were also used, the two methods, as expected, showing general agreement. In Table III the incidence of improvement as assessed by the doctor was not significantly greater in the " meprobamate group " (P > 0-05), although this group tended to do better. In this comparison, for statistical purposes, the patients were considered to be either improved or unimproved and a one-tail test used. The self-rating of the 36 patients showed significantly better response with meprobamate (C.R. = 1 98; 0-02 < P < 0 05). If the other four patients are taken into account the difference is not significant. Table IV shows that all symptoms tend to improve during the trial and with one exception those receiving meprobamate have a greater tendency to improve. The exception is the symptom of depression, where the greater number of patients improved with placebo. Anxiety, phobic-compulsive phenomena, and perhaps feelings of tension are improved in the meprobamate group to a statistically significant greater degree. Anxiety in those 36 completing the trial showed a highly significant improvement with meprobamate, 15 out of 17 improving with meprobamate and only eight out of 19 with placebo (C.R. = 3; P < 0-01). Even if the other four of the total series, including the three on meprobamate admitted to hospital unimproved, are taken into account the improvement is still significant (C.R. = 2 29; 0-01 < P < 0025). The number of patients whose symptoms of tension improved to the rating of " much better " was significantly greater with meprobamate in those completing the trial (C.R. = 174; 0-01 < P < 0 05), but just fails to reach this level if those admitted to hospital are taken into account as unimproved (C.R. = 1-6; P > 005). The phobic and compulsive group of symptoms was improved in a greater proportion of patients with meprobamate (C.R. = 2-01; 0-01 < P < 0-05) and it still reaches thc 5% level of significance if all 40 patients are considered (C.R. = 1-86; one-tail test; 0-01 < P < 0 05). Sleep, appetite, somatic pains, which include headaches and depression, did not show any significant degree of difference between the two groups.
The side-effect most often noticed by the patient was drowsiness, nine of the 20 patients receiving 400 mg. meprobamate q.d.s. felt drowsy for periods from two days up to two weeks, by which time the effect had worn off. One patient receiving placebo complained of the same thing for a few days. This difference between the two groups is significant (x2 = 6 5; d.f. = 1; P < 0-02). One (1956) . Sim feeling of tension is decreased in these I described frequently in other report, Walton, and Black, 1957 
